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Abstract
Background: Ankylosing spondylitis (AS) is characterised by immune-mediated arthritis and osteoproliferation,
ultimately leading to joint ankylosis. Whether inflammation is necessary for osteoproliferation is controversial,
fuelled by the unclear efficacy of anti-inflammatory treatments on radiographic progression. In proteoglycan-
induced spondylitis (PGISp), a mouse model of AS, inflammation is the prerequisite for osteoproliferation as
osteoproliferation was only observed following inflammation-driven intervertebral disc (IVD) destruction. We
hypothesised that early intervention with a potent anti-inflammatory therapy would protect IVD integrity and
consequently alter disease progression.
Methods: PGISp mice received vehicle or a combination of etanercept (ETN) plus prednisolone (PRD) therapy for 2 or
6 weeks initiated at an early disease stage. Peripheral arthritis was scored longitudinally. Spinal disease was assessed
using a semi-quantitative histological scoring regimen including inflammation, joint destruction and excessive tissue
formation.
Results: ETN + PRD therapy significantly delayed the onset of peripheral arthritis. IVD integrity was significantly
protected when treatment was commenced in early disease. Six-weeks of treatment resulted in trends towards
reductions in intervertebral joint damage and excessive tissue formation. IVD score distribution was dichotomized, likely
reflecting the extent of axial disease at initiation of therapy. In the sub-group of mice with high IVD destruction scores,
ETN + PRD treatment significantly reduced IVD destruction severity, inflammation and bone erosion and reduced
cartilage damage and excessive tissue formation.
Conclusions: Early intervention with anti-inflammatory treatment not only improved inflammatory symptoms but also
ameliorated structural damage of spine in PGISp mice. This preclinical observation suggests that early anti-inflammatory
intervention may slow radiographic progression in AS patients.
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Background
Ankylosing spondylitis (AS) is a debilitating spondyloar-
thropathy which predominantly affects the spine and
pelvis. The disease initially presents as inflammation
followed by osteoproliferation that can result in axial
joint fusion and bone formation at inflamed entheses
[1]. In many countries, first-line treatment recommenda-
tions involve the use of non-steroidal anti-inflammatory
drugs (NSAIDs) and physiotherapy. Use of TNF-inhibitors
is restricted to patients fulfilling the modified New York
classification criteria for AS (i.e. presence of osteoprolifera-
tive changes in the sacroiliac joints required) [2] and who
have failed NSAID therapy [3]. Both treatment approaches
are effective at relieving inflammatory symptoms and sup-
pressing objective measures of joint inflammation. How-
ever, it is not clear whether anti-inflammatory treatments
retard progression of syndesmophyte formation, indicative
of disease-associated osteoproliferation.
Recent reports have suggested that anti-TNF treatment
can retard late stage disease [4, 5]. However, delayed
diagnosis [6] and/or delayed treatment delivery [4],
which frequently occur in AS, are associated with higher
radiographic progression rates. Additionally, presence of
syndesmophytes at anti-TNF treatment commencement is
prognostic of radiographic progression [7] indicating that
anti-TNF treatment may be less effective if structural
damage is established. Hence, a “window of opportunity”
[8] might exist early in AS during which optimal long-
term benefit will be gained from initiating TNF-inhibitors
or alternative anti-inflammatory therapies.
There is conflicting evidence regarding osteoprolifera-
tion dependence on inflammatory mechanism in AS.
Anti-TNF treatment in the human leukocyte antigen-B27/
human β2-microglobulin (HLA-B27/hβ2m) transgenic rat
model decreased inflammatory symptoms but failed to
inhibit activation of signalling pathways responsible for
chondroproliferation [9]. Similarly, induction of osteo-
phyte formation in the human TNF transgenic mouse
arthritis model required the additional hit of Dickkopf-1
blockade [10]. The most compelling data comes from
human magnetic resonance imaging (MRI) studies suggest-
ing that whilst syndesmophytes are more likely to develop
at vertebral corners with prior evidence of inflammatory or
fatty lesions, many syndesmophytes occur without evidence
of such changes [11]. However, the insufficient sensitivity
of MRI to low grade inflammatory changes that may be the
precursor of syndesmophyte formation, or the possibility
that inflammation at vertebral corners is episodic in nature,
limits the specificity confidence of this technical approach
[12]. No superior imaging modalities are available and
human histopathological studies are limited by the difficul-
ties associated with accessing involved joints. Therefore,
mouse models must be utilized to investigate the relation-
ship between inflammation and osteoproliferation.
The proteoglycan-induced spondylitis (PGISp), a mouse
model of AS, is accompanied with peripheral arthritis
allowing a visual diagnosis of early inflammatory events
[13]. An advantage of this mouse model is that both
inflammation and osteoproliferation are evident in the
spine [14]. Slow progression of structural changes and
high heterogeneity between individual animals and
between joints within the same individual, while experi-
mentally challenging, are similar to disease progression
and characteristics observed in AS patients [15]. Using this
model, we recently reported that the axial disease initiated
as a intervertebral joint associated inflammatory response
leading to intervertebral disc (IVD) destruction. We postu-
lated that IVD destruction subsequently increased axial
mechanical stress, joint damage and ultimately excessive
tissue formation, as an aberrant repair response [16]. Con-
sequently, suppressing inflammation prior to irreparable
IVD damage might be an effective therapeutic approach
for preventing or ameliorating progression of AS [16].
The objective of this study was to interrogate whether
early and aggressive anti-inflammatory treatment is
effective at preventing inflammation and whether this
ultimately prevented/reduced progression to osteoproli-
feration. To achieve this we used an aggressive combin-
ation anti-inflammatory therapy that was initiated in
the early, predominantly inflammatory phase of disease
in the PGISp mice AS model [16]. The combination
anti-inflammatory therapy was supra-clinical dosing of
etanercept (ENT, a soluble TNF decoy receptor) plus
prednisolone (PRD, a potent glucocorticoid). Supra-
clinical doses were utilised to achieve robust and broad
spectrum immune-suppression. Impacts of this combin-
ation treatment over short- and long-term interventions
were assessed using clinical scoring and semi-quantitative
histopathological approaches.
Methods
Animals
All experimental procedures were approved by The
University of Queensland animal ethics committee and
adhered to by the Australian code for the care and use
of animals for scientific purposes. In order to achieve
100% disease penetrance and robust severity, disease
was induced as described previously [14] in 12-week-
old IL4-deficient female BALB/c mice by intraperito-
neal injection of partially purified cartilage extract
(equivalent with 100 μg core protein of human cartilage
proteoglycan (PG)) emulsified with 2 mg dimethyldioc-
tadecylammonium bromide (DDA, Sigma-Aldrich, St.
Louis, MO) in a total volume of 200 ml phosphate-
buffered saline (PBS, pH 7.4) at day 0, and then boosted
with 150 ml emulsion on weeks 3 and 6.
PGISp mice were treated with vehicle or ETN plus
PRD (ETN + PRD). Mice were distributed randomly to
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treatment groups at first PG priming injection. ETN
(provided by Pfizer, NY, USA) was administered at
10 mg/kg by subcutaneous injection 3 times a week.
PRD was administered at 1.5 mg/kg/day by a slow-
release pellet (Innovative Research of America, Sarasota,
FL, USA) implanted subcutaneously (Fig. 1a). Vehicle
groups were treated with PBS by subcutaneous injection
with or without placebo pellets. All treatments started
6.5 weeks post the initial PG priming injection, so that the
immune response was primed and re-activated in the
absence of any anti-inflammatory treatment. ETN + PRD
treatments were continued for 10 days (short-term,
6.5–8 weeks) or ~6 weeks (long-term, 6.5–12-weeks)
(Fig. 1a). Peripheral inflammatory symptoms were scored
ranging from 0 to 3 based on the degree of redness and
swelling three times weekly. Cumulative arthritis scores of
the four paws are presented as per previously [17]. Mice
were euthanized at the end of each of the assigned treat-
ment regimens and tissues collected for histological analysis.
Histology and semi-quantitative score
Dissected thoracic to lumbar spines were decalcified,
processed and sectioned (4 μm) in the sagittal plane.
Sections were processed for standard haematoxylin and
eosin (H&E) and toluidine blue staining as described
previously [16].
A semi-quantitative histological scoring criterion
based on H&E stain and toluidine stain was used to
assess axial disease progression [16]. Briefly, the score
for an intervertebral joint was produced by averaging
the scores of ventral (anterior) and dorsal (posterior)
aspects. An overall average score for each animal was
then generated by averaging the scores for all assessable
intervertebral joints in each sample (range 6 to 24 inter-
vertebral joints scored in each sample (median = 13)).
Inflammatory score: 0, no evident inflammatory infil-
trate; 1, inflammation present at periphery of the IVD; 2,
inflammatory pannus smaller than 50% IVD area; 3, in-
flammatory pannus invading more than 50% IVD area.
IVD destruction score: 0, no evident disc destruction; 1,
less than 50% disc destruction; 2, more than 50% disc
destruction; 3, complete disc destruction. Bone erosion
score: 0, no erosion; 1, one or a few small areas of re-
sorption in original vertebral bone; 2, numerous areas of
obvious focal resorption in original vertebral bone or
several areas of severe destruction. Cartilage damage
score: 0, no evident cartilage damage; 1, some loss of
endplate cartilage and/or growth plate cartilage; 2, severe
loss of endplate cartilage and some growth plate cartilage
damage. 3, severe loss of both endplate and growth plate
cartilages. Excessive tissue formation score: 0, no evident
mesenchymal cells or chondrocytes around IVD; 1,
Fig. 1 Axial disease progression and treatment regimen. Archetypical features of PGISp axial disease. a A representative image of an inflamed
intervertebral disc (IVD) in which inflammatory cells (black arrow head) accumulate around the vertebral joint and invade the IVD space. Part of
IVD has been destroyed, but there is still residual IVD tissue evident (asterisk). b H&E and c toluidine blue stained sections showing a representative
example of a severely affected vertebral joint in which the IVD is destroyed with clear evidence of cartilage end plate (black arrows) and bone destruction
(yellow arrow heads) plus evidence of osteoproliferation (red arrow heads). Scale bars: 200 μm. d Schematic representation of PGISp induction
and anti-inflammatory treatment regimen. PGISp mice were treated with vehicle or ETN + PRD started 3 days after the third PG injection
(“week 6.5”) and continued either until the end of week 8 (short-term) or week 12 (long-term) post-priming. Tissues were harvested at the end
of each treatment period. Blue arrows indicate the initiation of treatment. Red arrows indicate tissue harvests. Open arrows indicate the
treatment period
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mesenchymal cell invasion/expansion; 2, fibrocartilage for-
mation smaller than 50% of the original disc area; 3. fibro-
cartilage formation larger than 50% of the original disc
area. Intervertebral joints that scored one or greater in
any of the criteria described above were defined as
affected joints. PGISp mice with at least one involved
inter-vertebral joint were considered as affected mice. The
incidence of axial disease was the percent of affected
mice within the group. The axial disease penetrance
was defined as the percent of affected intervertebral
joints within an individual mouse. Based on expert
biostatistical advice from QFAB Bioinformatics, further
subgrouping of mice into low and high disease activity
was based on median IVD destruction score (vehicle: 1.05
and ETN + PRD: 0.66).
Statistics
Mann-Whitney tests were used to determine statistically
significant differences in univariate analyses. The rela-
tionship between histological features was determined
by Spearman correlations. These statistical analyses were
performed using PRISM 6 (GraphPad Software, La Jolla,
CA). The statistical significant differences between the
proportions of outcomes between treatment groups were
determined using one-tailed Z-tests (http://epitools.aus-
vet.com.au/content.php?page=home). P values less than
0.05 were considered significant in the present study.
Results
Anti-inflammatory intervention dampened systemic
inflammation in the PGISp model
We designed and implemented an early and intensive
anti-inflammatory therapeutic approach in the PGISp
model. Our intention was to initiate treatment post dis-
ease initiation but prior to irreversible IVD destruction
[16]. In the absence of useful serum markers of axial
disease progression (Additional file 1: Figure S1), we se-
lected the treatment commencement point based on our
previously reported histology evidence showing that 60
and 100% of PGISp mice exhibited axial inflammation
(Fig. 1a) by weeks 6 and 8 post initial priming, respect-
ively. Clear progression of IVD destruction (Fig. 1a) was
seen in more than 50% of mice by 8 weeks post-priming
with peak IVD destruction severity reached by 10 weeks
with 100% of mice affected [16]. Extensive osteoproli-
feration (Fig. 1b and c) was observed at the affected
intervertebral joints initiating 8 weeks post initial priming
[16]. Accordingly, the treatment regimen in the present
study was initiated 6.5 weeks post-priming to achieve a
“therapeutic” delivery prior to development of irreversible
IVD changes. Impacts of both short- and long-term ther-
apies were examined with mice harvested either 2 or
6 weeks post-treatment initiation (Fig. 1d). The proportion
of mice with no disease or peripheral and/or axial disease
within each therapy arm was determined (Table 1). Clin-
ical scores of peripheral joints were used to longitudinally
assess systemic disease activity. Axial disease was assessed
by histopathology with detection of one or more of the
scored histopathological features being deemed as pres-
ence of axial disease. Eight weeks after PG priming, 80%
of vehicle treated mice had evidence of peripheral and/or
axial disease; in contrast, only 14% of mice in the
ETN + PRD treated group had both. All mice developed
evidence of disease 12 weeks post-priming irrespective of
treatment. In the vehicle-treated group, 100% exhibited
both peripheral and axial disease. In contrast, in
ETN + PRD-treated mice only 62.5% had peripheral plus
axial disease, indicating greater variance in systemic dis-
ease after early anti-inflammatory therapy. Taken together,
these observations indicate that early treatment with
ETN + PRD had robust short-term efficacy.
Early ENT-PRD intervention transiently suppressed severity
of peripheral arthritis
The onset of peripheral arthritis varied between individual
mice, with the earliest onset observed 4 weeks post priming
(Fig. 2) and no significant difference was observed in per-
ipheral disease incidence at the time of therapy initiation
between any of the treatment groups (Table 1). In vehicle-
treated mice (Fig. 2, dashed line), the peripheral arthritis
score increased from 4 weeks post-priming followed by an
accelerated progression after the third PG injection and
then “levelled off” until the end of experimental period. In
ETN + PRD-treated mice (Fig. 2, solid line) the initial acute
arthritis (between weeks 4 and 6.5) was suppressed imme-
diately after the first treatment, and remained negligible for
2–3 weeks. Within this period (from the beginning of
ETN + PRD until week 9), there was a significant differ-
ence in peripheral paw inflammation between the vehicle-
injected and ETN + PRD-treated groups (Fig. 2, p < 0.05).
Hence, the ETN + PRD treatment regimen delayed and
suppressed the peripheral disease development.
Early ENT + PRD intervention suppressed axial
inflammation and ameliorated both destructive and
osteoproliferative disease outcomes
ETN + PRD treatment impacted the incidence, pene-
trance, severity and progression of the axial disease. Spe-
cific features of axial disease activity in each animal were
assessed using semi-quantitative histological scoring of
spine sections. Due to disease severity being variable
between intervertebral joints within individual animals
(Additional file 2: Figure S2), global impact of treatments
on the specific disease features was assessed by generating
an average histopathological feature score for each
spine (Additional file 2: Figure S2). ETN + PRD treat-
ment significantly reduced the penetrance of axial dis-
ease (percent of affected intervertebral joints within an
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individual animal) in both short-term and long-term
treatment arms (Fig. 3a).
When compared with vehicle controls, ETN + PRD
treatment significantly suppressed axial inflammation in
both treatment arms (Fig. 3b) supporting the effectiveness
of the ETN + PRD regimen on spondylitis. IVD destruc-
tion (Fig. 3c), bone erosion (Fig. 3d), and cartilage damage
(Fig. 3e) were evident in both short- and long-term vehicle
control groups (Fig. 3f). Within the short-term ETN + PRD
treatment, scores for IVD destruction and bone erosion
were significantly lower than controls with a similar trend
toward reduction in cartilage damage and excessive tissue
formation (Fig. 3).
In the long-term treatment arm, scores for disease fea-
tures in the vehicle treated group were non-parametric
and exhibited a wide degree of variation (Fig. 3). When
data points for the different histopathological features
were paired for individual animals, it was clear that a sub-
set (3 of 8 mice, Fig. 3, data points highlighted by the
dashed boxes) of ETN + PRD treated mice had minimal
or undetectable axial disease as indicated by no or little
evidence of disc destruction, bone erosion, cartilage dam-
age or excessive tissue formation (Fig. 3, boxed area). All 3
of these mice had detectable peripheral disease confirming
successful disease induction.
While inflammation is not a robust indicator of axial
disease progression with a non-linear disease process,
IVD destruction is an irreversible event, and therefore
its presence is a constant mark of previous disease activity.
In the long-term vehicle treatment arm, IVD destruction
scores significantly and positively correlated with bone
erosion, cartilage damage and excessive tissue formation
scores (Fig. 4a). In ENT + PRD long-term treated mice
the correlation of IVD destruction with cartilage damage
and excessive tissue formation was upheld, but bone ero-
sion scores no longer correlated (Fig. 4b). Interrogation of
the IVD destruction data distribution in the long-term
treatment arm supported dichotomization of this data set
with mild and severe disease courses defined by low ver-
sus high IVD destruction. Consequently sub-groups were
segregated based on the median IVD destruction score
(vehicle: 1.05 and ETN + PRD: 0.66).
When comparing the low IVD destruction sub-groups,
there was no significant difference between treatments
across all histopathological criteria (not shown). When
comparing high (H)-ETN + PRD with H-Vehicle, the
Fig. 2 Early intervention delays and suppresses peripheral disease progression. Peripheral arthritis progression of mice receiving vehicle
(open circle, N = 12) and ETN + PRD (filled circle, N = 15) in both treatment arms. The line up to the week 8 point includes mice from both
the short-term and long-term treatment groups, as these animals are directly comparable up to this point. The line from week 9 to 12 includes
only long-term treatment group mice. Cumulative arthritis score (inflammation of all 4 limbs of all animals are shown (mean ± SD). Animal
numbers per group are listed in Table 1
Table 1 Incidence of peripheral and axial disease
Treatment (treatment period) Vehicle (6.5–8) ETN + PRD (6.5–8) Vehicle (6.5–12) ETN + PRD (6.5–12)
Both peripheral and axial disease 80% 14.3% (p = 0.01) 100.0% 62.5% (p = 0.035)
Peripheral disease only 0 14.3% 0.0 25%
Axial disease only 20% 42.9% 0.0 12.5%
Presence of axial disease 100% 57.1% (p = 0.02) 100.0% 75% (p = 0.0015)
Incidence of peripheral disease 80% 28.6% 100% 87.5%
Peripheral disease incidence at
treatment commencement
40% 28.6% 57.1% 62.5%
Total number 5 7 7 8
The statistical significance of data was analysed by one-tailed Z-tests compared with vehicle at corresponding time points
Abbreviations: ETN etanercept, PRD prednisolone
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mean IVD destruction score was significantly lowered by
ETN + PRD (Fig. 4c). Furthermore, H-ETN + PRD had
significantly lowered percent of affected IVD (Fig. 4d),
inflammation (Fig. 4e) and bone erosion scores (Fig. 4f ).
Trends toward treatment-induced lowering of cartilage
damage (Fig. 4g) and excessive tissue formation (Fig. 4h)
were also noted. Overall, in this sub-group of mice that
had a more severe clinical progression, early interven-
tion with ETN + PRD treatment ameliorated axial
disease severity.
Discussion
The PGISp mouse model of AS was used to address whether
early intervention of an aggressive anti-inflammatory drug
regimen could alter broad aspects of the disease course,
particularly retardation of irreversible joint changes.
The study was also designed to inform on the depend-
ence between early inflammatory processes and ongoing
destructive changes in this AS model [16]. We observed
delayed progression and reduced severity of peripheral
disease in the first 2–3 weeks of ETN + PRD treatment.
Histological analysis demonstrated that this transient sys-
temic suppressive effect of anti-inflammatory treatment
was associated with longer term significant reductions in
axial inflammation, number of affected axial joints and
vertebral joint destruction as well as declining trends in
excessive tissue formation. Notably, the chosen anti-
inflammatory treatment also clearly decreased disease
activity compared to vehicle even in mice that exhibited a
more severe disease course.
In the present study, early intervention with ETN + PRD
clearly decreased bone erosion and weakened its associ-
ation with IVD destruction. These observations provide
further support that this destructive disease outcome is a
direct result of the inflammatory process [16]. While IVD
destruction was significantly ameliorated by the anti-
inflammatory therapy it was not completely abated, and in
joints with compromised IVD, progressive excessive tissue
formation was observed. This provides support in favour
of the hypothesis that IVD destruction-induced structural
instability plays an important role in driving osteoproli-
ferative outcomes. Increased intervertebral body mechan-
ical forces as a consequence of IVD damage/loss may
promote local bone formation through differentiation of
osteoprogenitor cells as a consequence of elevated
mechanosensing signals [18]. This is in agreement with
clinical studies showing that presence of syndesmophytes
when treatment commenced strongly predicted radio-
graphic progression regardless of treatment [7].
The PGISp model recapitulates many key features of
AS, including variability in disease onset and heterogen-
eity in disease severity both between and within individ-
uals [15, 16]; while this variability makes it a good AS
model, it confounded the current study outcomes by
reducing statistical power. Peripheral disease is not an
accurate predictor of axial disease and consequently can-
not be used to reliably inform appropriate treatment
Fig. 3 Early anti-inflammatory intervention ameliorates axial disease progression. a Penetrance (percent of affected inter-vertebral joints within all
inter-vertebral joints scored in the same spine) and the histological scores of b inflammation, c IVD destruction, d bone erosion, e cartilage damage,
and f excessive tissue formation. Vehicle (open circle. 6.5–8 weeks, N = 5; 6.5–12 weeks, N = 7) and ETN + PRD (filled circle, 6.5–8 weeks, N = 7; 6.5–
12 weeks, N = 8). Each symbol represents one mouse in the group and the results are presented as mean ± SD. Symbols in dashed boxes indicate
mice with minimal axial disease. The statistical significance of data was analysed by Mann-Whitney analysis
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initiation. In the absence of a sufficiently sensitive in vivo
longitudinal imaging approach to detect spinal inflamma-
tion, therapy initiation could not be uniformly initiated at
a defined and consistent threshold of axial disease devel-
opment. Therefore treatment initiation was based on a
fixed time post-priming that was selected based on our
previously reported axial disease time course data [16].
Study outcomes were further limited by the fact that the
length of study, which was dictated by anti-inflammatory
therapy delivery limitations, did not extend to permit peak
attainment of osteoproliferative tissue formation in the
vehicle control group [16]. Consequently the current
study was underpowered for robust assessment of some
disease features. Nevertheless, the data provide clear
evidence of beneficial impact of an early and aggressive
anti-inflammatory intervention across a broad range of
AS-like disease characteristics. Extended time course
studies in larger cohorts will be required to definitively
dissect the effects of early anti-inflammatory interventions
on late-stage disease outcomes.
The results of the current study provide further sup-
port to the concept that inflammation and osteoproli-
feration in AS are dependent but sequential events.
Accordingly the results advocate that early intervention
Fig. 4 Early intervention reduced axial disease in more severely affected mice. a IVD destruction is strongly correlated with bone erosion (circle),
cartilage damage (square) and excessive tissue formation (triangle) in long-term vehicle-treated PGISp mice (N = 7). The positive correlation is also
present in the ETN + PRD group, with the exception of bone erosion (N = 8) b. PGISp mice in vehicle group were sub-grouped into low disc
destruction and high disc destruction (H-Vehicle, filled circle, N = 4) in relation to the median score (1.50). ETN + PRD-treated mice were split
into low disc destruction and high disc destruction (H-ETN + PRD, filled square, N = 4) in relation to the median score (0.66): Semi-quantitative
histological scores for c IVD destruction, d percentage of affected IVDs, e inflammation, f bone erosion g cartilage damage and h excessive
tissue formation. Each symbol represents one mouse in the group and the results are presented as mean ± SD. The statistical significance of
data was analysed by Mann-Whitney analysis
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with effective anti-inflammatory treatment in AS has a
high potential to prevent both primary joint destruction
and secondary osteoproliferative responses. However this
study does not preclude usefulness of anti-inflammatory
treatments in established disease. Specifically, aggressive
anti-inflammatory therapy did ameliorate disease in mice
that had a more progressed and severe disease course.
Conclusion
This study highlights the importance of improving
early diagnostic methods, particularly with respect to
axial inflammation, in order to inform better clinical
management of AS.
Additional files
Additional file 1: Figure. S1. Serum IL-17 and CRP concentration does
not changed during disease progression. Serum samples were collected
from 6, 8, 10, 12, 16, 24 weeks post the first PG injection as reported
previously [16] (A) Serum IL-17 was measured using the IL-17A ELISA MAX™
Deluxe set (BioLegend) as per the manufacturer’s instructions. (B) Serum
CRP concentrations were analysed using mouse CRP ELISA DuoSet kit (R&D
system, DY1829, Minneapolis, Minn., USA) as per the manufacturer’s
instructions. There was no significant difference between naïve and any
time points post PG-priming. Data is presented as mean ± SD. The
statistical significance was analysed by Kruskal-Wallis test followed by
Dunn’s multiple comparisons test. (TIFF 54 kb)
Additional file 2: Figure. S2. Representative images of IVDs with more
severe axial disease. Representative images of H&E stained sections
containing a portion of each spine within the field of view. A representative
mouse exhibiting more severe axial disease severity scores from each of the
PGISp experimental groups is shown: (A) vehicle 6.5–8 weeks, (B) ETN + PRD
6.5–8 weeks, (C) vehicle 6.5–12 weeks (D) ETN + PRD 6.5–12 weeks. The
fields of view exemplify the variability between intervertebral joints within
individual spines including unaffected joints with preserved IVDs (open
arrows). A and B) In the short-term treatment groups inflammatory features
are still prominent as illustrated by presence of immune cell infiltrates (arrow
heads) in both (A) vehicle and (B) ETN + PRD treated groups. In (A)
inflammatory scores for each of the intervertebral joints denoted (a) through
(d) were 2, 2.5, 1.5 and 0 respectively, with 4 of the 11 intervertebral joints
that were scored for this sample shown (total spine score for inflammation
in this sample was 0.82). In (B) inflammatory scores for intervertebral joints
denoted (a) through (c) were 0, 0.5 and 1 respectively, with 3 of the 24
intervertebral joints scored for this sample shown (total spine score for
inflammation in this sample was 0.15). C and D) In long-term treatment
groups, IVD destruction and excessive tissue formation (black arrows) are
evident in both vehicle (C) and ENT + PRD (D) treated animals. In (C)
excessive tissue formation scores for intervertebral joints denoted (a)
through (e) were 2, 1.5, 0, 2 and 2 respectively, with 5 of the 8 intervertebral
joints scored for this sample shown (total spine score for excessive tissue
formation in this sample was 1.44). In (D) excessive tissue formation scores
for intervertebral joints denoted (a) through (f) were 1, 0, 0, 0, 0 and 2
respectively, with 6 of the 17 intervertebral joints scored in this sample
shown (total spine score for excessive tissue formation in this sample was
0.29). Scale bar (A-B) 500 μm (C-D) 1 mm. (TIFF 25040 kb)
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